Finasteride-Induced Gynecomastia in a 62-Year-Old Man
June 1995
in “The American Journal of the Medical Sciences”
TLDR Finasteride caused enlarged breast tissue in a 62-year-old man.
This document reports a case of gynecomastia (enlarged breast tissue) in a 62-year-old man who was taking finasteride, a drug used to treat hair loss and prostate enlargement. The authors suggest that the reduction in DHT levels, along with a possible increase in estrogen levels, may have altered the androgen/estrogen ratio and led to the development of gynecomastia. They recommend close clinical follow-up for patients taking finasteride to monitor for potential systemic side effects.
View this study on amjmedsci.org →
Cited in this study
research Prolonged treatment with finasteride (a 5α-reductase inhibitor) does not affect bone density and metabolism
Long-term finasteride use doesn't change bone density or metabolism.
research C19and C215β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*
Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
Related
research Finasteride-Induced Gynecomastia in a 62-Year-Old Man
Finasteride caused enlarged breast tissue in a 62-year-old man.
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
Finasteride doesn't affect hormone levels in normal men.